Accéder au contenu
Merck
Toutes les photos(1)

Documents

Y0000218

Ondansetron hydrochloride dihydrate

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one hydrochloride, GR 38032F

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C18H19N3O · HCl · 2H2O
Numéro CAS:
103639-04-9
Poids moléculaire :
365.85
Numéro MDL:
MFCD00374371
Code UNSPSC :
41116107
ID de substance PubChem :
329830885
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

ondansetron

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

Cl[H].[H]O[H].[H]O[H].Cc1nccn1CC2CCc3c(C2=O)c4ccccc4n3C

InChI

1S/C18H19N3O.ClH.2H2O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2;;;/h3-6,9-10,13H,7-8,11H2,1-2H3;1H;2*1H2

Clé InChI

VRSLTNZJOUZKLX-UHFFFAOYSA-N

Informations sur le gène

human ... HTR3A(3359)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ondansetron hydrochloride dihydrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

5-HT3 serotonin receptor antagonist

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1478618

Ondansetron Related Compound C, United States Pharmacopeia (USP) Reference Standard

1478593

Ondansetron Related Compound A, United States Pharmacopeia (USP) Reference Standard

1478629

Ondansetron Related Compound D, United States Pharmacopeia (USP) Reference Standard

1478582

Ondansetron hydrochloride, United States Pharmacopeia (USP) Reference Standard

1478630

Ondansetron Resolution Mixture, United States Pharmacopeia (USP) Reference Standard

PHR1181

2-Methylimidazole (Ondansetron Impurity F), Pharmaceutical Secondary Standard; Certified Reference Material

Y0000195

Ondansetron impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000196

Ondansetron for TLC system suitability, European Pharmacopoeia (EP) Reference Standard

Y0000197

Ondansetron for LC system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001326

Imidazole, European Pharmacopoeia (EP) Reference Standard

Y0001320

Ondansetron impurity F, European Pharmacopoeia (EP) Reference Standard

Y0001345

Ondansetron impurity A, European Pharmacopoeia (EP) Reference Standard

Y0001346

Ondansetron impurity G, European Pharmacopoeia (EP) Reference Standard

1478571

Ondansetron, United States Pharmacopeia (USP) Reference Standard

BP808

Ondansetron hydrochloride dihydrate, British Pharmacopoeia (BP) Reference Standard

BP806

Ondansetron impurity standard, British Pharmacopoeia (BP) Reference Standard

PHR2224

Ondansetron Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2223

Ondansetron Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2221

Ondansetron Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Skull and crossbonesCorrosionEnvironment
GHS06,GHS05,GHS09

Mention d'avertissement

Danger

Mentions de danger

H301,H318,H410

Classification des risques

Acute Tox. 3 Oral - Aquatic Acute 1 - Aquatic Chronic 2 - Eye Dam. 1

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 1

1 of 1

Acétaminophène European Pharmacopoeia (EP) Reference Standard

P0300000

Acétaminophène

Kristi L Kinder et al.
Pediatric emergency care, 28(11), 1203-1205 (2012-11-02)
The objective of this study was to determine if overweight children are more likely than normal-weight children to require ondansetron when undergoing ketamine sedation in a pediatric emergency department. Patients between the ages of 2 and 18 years with an
Mehrdad Kashifard et al.
Clinical and experimental obstetrics & gynecology, 40(1), 127-130 (2013-06-04)
Nausea and vomiting of pregnancy (NVP) are seen in 50-80% of pregnancies. However, in severe NVP, called hypermesis gravidarum (HG), medical therapy to reduce nausea and vomiting is inevitable and ondansetron (OND) as an effective drug has recently been proposed.
Hitendra S Mahajan et al.
Carbohydrate polymers, 91(2), 618-625 (2012-11-06)
The objective of present study was to enhance bioadhesive potential of xyloglucan by thiolation. Thiolation of xyloglucan was achieved with esterification with thioglycolic acid. Thiolated xyloglucan was characterized by NMR, DSC, and XRD analysis. Thiolated xyloglucan was determined to possess
João Maria Corrêa Filho et al.
Addictive behaviors, 38(4), 2044-2051 (2013-02-12)
Ondansetron has emerged as a promising medication for the treatment of alcohol dependence, mainly among early-onset alcoholics. This research primarily aimed to evaluate the efficacy and safety of ondansetron at a 16mg/day dosage to treat alcohol-dependent outpatients. A double-blind, placebo-controlled
Ali Mujtaba et al.
Drug testing and analysis, 5(2), 122-125 (2013-02-16)
A new, simple, rapid, accurate and precise high performance thin layer chromatography (HPTLC) method has been developed for the estimation of ondansetron hydrochloride in bulk and sublingual tablets. The mobile phase composition was chloroform : ethyl acetate : methanol :
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique